alterations in cancer. Thus, it is not surprising that miRs are dysregulated in cancer and associated with cancer development, metastasis, and drug resistance [9] . Additionally, 60% of protein coding genes are predicted to be subject to regulation by miRs, further emphasizing their role in cellular processes, normal and otherwise. [10] . miRs act as tumor suppressors or oncogenes depending on the function of their target genes, therefore cancer cells modulate miR expression by different mechanisms (mutations, epigenetic marks, etc.) to promote tumorigenicity [3, 5] . The most recognized oncogenic miRs include the miR-17~92 cluster, as well miR-21, and miR-155 [5] ; overexpression of these miRs has been documented in several cancers. miR17~92 is located in intron 3 of the C13orf25 gene at 13q31.3, a genomic region commonly amplified in most hematological and solid malignancies. This cluster of miRs has been shown to act with the c-myc oncogene to accelerate B lymphomagenesis in an in vivo B cell lymphoma model [11] . Commonly recognized tumor suppressor miRs include miR-34a and let-7a [5] . It was shown that inhibition of the RNA binding protein Lin28 increased expression of let-7a and radio-sensitized A549 lung cancer cell line [12] . Strikingly, some miRs can act as tumor suppressors in one cancer and as oncogenes in other cancer [3] . For example, a recent study demonstrated that overexpression of miR-192 inhibits metastasis to liver in an orthotopic colon cancer murine model by repressing oncogenic Bcl-2 and VEGFA [13] . In another study, miR-192 was shown to be upregulated in high-risk neuroblastomas, where it silenced the tumor suppressor Dicer1 [14] .
In recent years, the role of extracellular vesicles (EVs) in cancer biology has attracted increasing attention. Despite a fundamental lack on consensus on the detailed classification of EVs, a general classification system has bee developed, where EVs are classified into 3 groups based on their size: exosomes (40-120 nm), microvesicles (50-1000 nm) and apoptotic bodies (500-2000 nm) [15] . The lipidic bilayer structure of the vesicles (as shown by electron microscopy) and the specific expression of surface markers also contribute to the characterization of EVs, according to the recently published guidelines by the International Society of Extracellular Vesicles [16] . Exosomes consist of a lipidic bilayer surrounding a small cytosol that is devoid of cellular organelles and is enriched in proteins and nucleic acids [17] . Exosomes were first discovered as transferrin associated 50 nm vesicles extruding from reticulocytes [18] . Exosomes are important mediators of intercellular communication both in disease and healthy states due to their ability to deliver protein and nucleic acid cargo between cells [19] . In 2007, Valadi et al. showed that exosomes contain miRs, which can be transferred inter-cellularly and are biologically active in the recipient cell [20] . Further studies supported the transfer of functional exosomal miRs (exo-miRs) between cells as mediators of conserved intercellular communication [21, 22] . As an example, T-cells uni-directionally transfer miRs to antigen presenting cells (APCs) by delivery of CD63+ exosomes on the immune synapse, and transferred miRs modulate gene expression in APCs [23] . The first evidence implicating exo-miR involvement in the communication among cancer cells came from Skog et al., who demonstrated that glioblastoma-derived exosomes contain miR-21 that is taken up by normal host cells and modulates target genes leading to increased proliferation of cancer cells [24] .
It is now well understood that cancer is not a disease localized to the cancer cells, but that cancer cells orchestrate changes to the surrounding tumor microenvironment (TME) to promote cancer growth [25] . Recent evidence has shown two important roles of miRs in the development and maintenance of the TME: dysregulated miRs in cancer cells mold the composition of the TME, and and miRs in the TME can act in a protumoral manner [26] . A plethora of studies is currently investigating the role of exo-miRs as direct bidirectional mediators of intercellular TME crosstalk. Cancer cells or the cells of TME directly and reciprocally transfer exosomic miRs to mediate phenotype changes in the TME and in the cancer cell. There is evidence that exosome secretion is increased in cancer, and exosomes represent one of the main mechanisms of crosstalk in the TME and in priming the metastatic niche [27, 28] .
Over the last few years, nuclease resistant extracellular miRs have been detected in all biological fluids (blood, serum, amniotic fluid, urine, breast milk, etc.) [29] . The secretory mechanisms of extracellular miRs are not yet well understood, but the resistance to of miRs to nucleases suggests some form of protective packaging during miR secretion. Proposed mechanisms of secretion include: (1) passive secretion from cells with short lives such as platelets or cells undergoing apoptosis or necrosis [30] , (2) active secretion of miRs bound to lipoproteins (e.g., high density lipoprotein (HDL)) or with RNA binding proteins (Argonaute 2 (Ago2)) [31] , and (3) vesicle-mediated secretion of miRs within exosomes, microvesicles and apoptotic bodies [20, 32] . The functions of extracellular miRs are not fully understood, but exomiRs are emerging as essential mediators of intercellular communication in the TME and as potential biomarkers of disease. Exo-miRs are gaining popularity as noninvasive biomarkers of disease that aid in the diagnosis, prognosis, and assessment of therapeutic response [33] .
In this review, we discuss the selective loading of miRs into exosomes and the role of exo-miRs in the cancer cell-TME communication to promote carcinogenesis. Specifically, we highlight our lab findings that cancer cell secreted exo-miRs bind to Toll like receptor 8 (TLR8) in tumor associated macrophages (TAMs) of the TME in a non-canonical manner to initiate pro-tumoral responses. Additionally, we describe the emerging role of exo-miRs as non-invasive biomarkers in cancer.
miR-selective sorting mechanisms in exosomes
Exosomes in the plasma of healthy humans have been shown to contain a diverse collection of RNA species, demonstrated by deep-sequencing of plasma-derived RNAs. Notably, miRs were among the most abundant type of exosomic RNA, comprising over 42.32% of all raw reads and 76.20% of all mappable reads [34] . On the other hand, Chevillet et al. isolated exosomes from diverse biological sources including healthy donor plasma, prostate cancer patient plasma, seminal fluid, and in vitro sources (human dendritic cells, ovarian cancer cells, and mast cells) and found low abundance of miRs in exosomes. They measured the number of exosomes in each sample by nanoparticle tracking analysis (NTA), isolated total RNA, and carried out a miR profiling array. In all of the samples, the ratio of selected overexpressed miR molecules to the number of individual exosomes was lower than one [35] . The miR pool in mesenchymal stem cells (MSCs) derived exosomes was also found to be 2-5% of total small RNAome. Nevertheless, the miRs in the MSC derived exosomes did not merely reflect the cellular content as a defined set of miRs was overrepresented in exosomes compared to the cell of origin [36] . More studies comparing the expression of miRs in cells and their EVs showed that some miRs were selectively secreted while others were specifically retained. For instance, miR-451 was the most exported miR in vesicles from HEK293 and multiple other cell types [37] .
Although the sorting mechanisms of miRs into exosomes are not fully understood and are the subject of ongoing research, four pathways of sorting have been described thus far [33] . The sorting pathways are: (1) the neural sphyngomyelinase 2 (nSMase2) dependent pathway [38] , (2) the miR motif and sumoylated heterogeneous nuclear ribonucleoproteins (hnRNPs)-dependent pathway [39] , (3) the 3'-end of the miR sequence dependent pathway [40] , and (4) the miR induced silencing complex (miRISC) related pathway [41] . Briefly, the presence of specific sequences in miRs controls their loading into a specific exosome, which is further regulated by proteins/enzymes that control miR sorting in a sequence-independent manner [33] .
Microarray analysis of exosomal and cellular miRs from human primary T lymphocytes in resting and activated conditions show that miRs modulated upon activation are not the same in cells and exosomes, a finding consistent with other studies [39] . Further analyses found that exo-miRs had two significantly over-represented motifs and cellular-miRs had three over-represented motifs. The exo-motif GGAG and the cellular motif UGCA occurred in the 3' half of the miR sequence in 75% and 66.6% of cases, respectively. Exosomes were isolated from primary human T-cell and incubated with streptavidin beads coated with either a biotinylated exo-miR (miR-198) or a cellular biotinylated miR-17 and pulled down proteins were subjected to mass spectrometry. The predominant precipitated proteins included hnRNPs. Among them, hnRNPA2B1 and hnRNPA1 seemed to bind only the biotinylated exo-miR-198. hnRNPA2B1 is an ubiquitous protein that has been shown to regulate mRNA trafficking to axons in neural cells. Specifically, hnRNPA2B1 binds a 21-nt RNA sequence called RNA trafficking sequence (RTS) in neurons to mediate mRNA transport. The mutagenesis of exo-miR motifs and modulation of hnRNPA2B1 expression affected miR sorting into exosome, suggesting an important role of hnRNPA2B1 in regulating miR-exosome sorting. Another study showed that perturbing miR or targeted transcript levels in the producer cells modulated miR sorting into exosomes [42] . The immortalized bone marrow-derived macrophages (iBMMs) were transduced with increasing concentrations of lentivirus (LV) overexpressing miR-511-3p, which is generally expressed at low levels in those cells. Upon overexpression, miR-511-3p levels were increased in the exosomes secreted by iBMMs relative to the cells. On the other hand, the overexpression of natural targets and artificial sequences complementary to miR-511-3p decreased miR-511-3p levels in iBMMs likely through a "miR sponge effect". However, miR-511-3p levels decreased more robustly in iBMM released exosomes than in the cells. Together these results suggest that miR sorting to exosomes is a controlled mechanism determined by the levels of targeted transcripts endogenously. A recent report shows that Ago2 plays an important role in stabilizing miRs and their secretion in EVs [43] . Ago2 is an important component of RISC complex involved in binding of small RNAs [44] . Ago2 overexpression in HeLa cells leads to: (1) increased expression of miR-16 in cells transfected with miR-16 mimic by protecting it from degradation in lysosomes, (2) increased miR-16 levels in cell secreted EVs implying Ago2 facilitates the packaging of secreted miRs, and (3) exogenous miR-16 delivered by EVs significantly reduced its target Bcl2 protein in recipient cells, and miR-16 and Bcl2 mRNA were physically bound with exogenous HA-tagged Ago2 [43] . Kosaka et al. were pioneers of investigating the mechanisms that affect miR sorting into exosomes [38] . They showed that horizontal transfer of miR-210 from metastatic cancer cells to microenvironment endothelial cells provides significant benefit to cancer cell survival. The inhibition of nSMase2 abrogated miR-210 transfer from cancer cells to endothelial cells and decreased metastasis. These findings suggest an important role of nSMase2 in loading of miR-210 onto exosomes.
Recent evidence suggests an important role of oncogenes in miR sorting to exosomes. The KRAS oncogene is commonly mutated in 35-45% of colorectal cancers (CRC). KRAS mutations are single nucleotide point mutations and these mutations impair the intrinsic GTPase activity of KRAS causing it to accumulate in the GTP-bound active form. The GTP-bound state leads to activation of downstream proliferative signaling pathways promoting cancer development [45] . The composition of small RNAs in the exosomes of isogenic CRC cell lines with wild type and mutated KRAS status were investigated. In both cases, the exosomes had distinct small RNA profiles compared to the cells. For example, the exosomes from mutant cells contained abundant miR-100, while whereas miR-10b was present at high levels in wild type exosomes. The inhibition of nSMase2 caused accumulation of miR-100 only in mutant cells implying KRAS mediated miRNA export [46] . Certain serotypes of human papillomaviruses (HPVs) cause cervical cancer. Honegger et al. determined how the intracellular and exosomal miR pool in HPVpositive tumor cells is affected by sustained expression of the viral E6/E7 oncogenes. RNA deep sequencing analysis showed abundance of pro-tumorigenic miRs such as miR-7-5p and miR-378a-3p in exosomes from cells expressing high levels E6/E7, further supporting the significant role of oncogenes in promoting miR loading onto exosomes [47] . Shen et al. showed that epidermal growth factor receptor (EGFR), a known oncogene in several cancers, suppresses maturation of several tumor suppressor miRs under hypoxic conditions by phosphorylating Ago2 [48] . Intriguingly, the EGFR interaction with Ago2 to inhibit maturation of miRs also implies that EGFR-dependent loading of pre-miRs onto exosomes [19] . The current evidence shows presence of both mature and pre-miRs in exosomes [19, 49] .
Interestingly, tumor suppressor genes also play a critical role in miR sorting to exosomes. Levine and colleagues have shown that the p53 regulated gene TSAP6 increases exosome production in p53 activated cells in response to stress [50] . Taking into account the importance of tumor suppressor genes in exosome production, Wei et al. showed that tumor suppressor Vps4A is downregulated in Human Hepatoma Cells (HCC) and it is involved in miR sorting into exosomes [51] . Upon ectopic expression of Vps4A in HCC, it was found that Vps4A enhanced secretion of oncogenic miRs in exosomes and as well accumulation of tumor suppressor miRs in cells. Overall, these studies represent a first attempt to decode the grammar behind miRNA sorting and uploading in exosomes. A better understanding of these mechanisms represents the first step to more effective strategies to engineer exosomic cargo for therapeutic purposes.
Exosomic miRs as key drivers of intercellular communication within the TME
The TME is composed of cellular and non-cellular components, and plays a fundamental role in the progression of cancer and in the acquisition of resistance to therapy [52, 53] . The cellular components are derived from both the tumor and the host. Host cells in the TME include Tumor-Associated Macrophages (TAMs), blood endothelial cells (BECs), lymphatic endothelial cells (LECs), carcinoma-associated fibroblasts (CAFs), and bone marrow derived mesenchymal stem cells (MSCs). The immune cells mediate anti-tumoral or pro-tumoral functions depending on their specific phenotype, such as anti-tumoral Th1 vs pro-tumoral Th17 subsets of CD4(+) T cells, anti-tumoral type I vs cancer promoting type II NKT cells, and M1 vs tumoral M2 macrophages. The noncellular components of the TME include the extracellular matrix (ECM), as well as the physical and chemical parameters (pH, oxygen tension, interstitial pressure, and fluid flux) [54] . Tumor progression requires cooperative and continuous intercellular communication between cancer cells and host cells [54] [55] [56] .
To escape immunity, cancer cells recruit inflammatory cells such as regulatory T cells that suppress T-cell based responses.
Intercellular communication in multicellular organisms is generally accomplished through direct cell-cell contact (e.g. nibbling) or transfer of secreted molecules (e.g. hormones, cytokines, chemokines) [21] . Secreted molecules can act over a short distance (autocrine and paracrine mechanisms) or travel long distances circulating in blood and body fluids (endocrine mechanism). Over the last few years, EVs have emerged as important mediators of intercellular communication in cancer, and are being investigated as essential mediators of intercellular communication in cancer and as cancer biomarkers. Specifically, exosomes are secreted in the extracellular space carrying miR cargo; they can then be transferred between cells or enter the general circulation.
Exosome
8 exosomes per 10 6 cells in a 24-hour period [57] . Interestingly, breast cancer exosomes isolated from metastatic breast cancer cells MDA-MB-231 and 4T1 showed significantly higher miR enrichment when compared to exosomes derived from the non-metastatic breast cancer cell line MCF7 [58] . Furthermore, breast cancer cell-derived exosomes contained pre-miRs that were associated with the RISC loading complex and displayed cell-independent capacity to process those pre-miRs into mature miRs; this is in contrast to exosomes isolated from normal cells, which lacked the miR processing machinery. Pre-miRs along with Dicer and Ago2 are present in breast cancer exosomes. Exosomes extracted from sera and cells of patients with breast cancer are able to transform nontumorigenic epithelial cells into malignant cancer cells that are capable of forming tumors in a Dicer-dependent manner [58] .
Most current evidence supports a pro-tumorigenic role for exo-miRs. However, one group showed that exosomes from the metastatic gastric cancer cell line AZ-P7a were enriched with the let-7 family of miRs that mostly act as tumor suppressors in a variety of malignancies. This study proposed that AZ-P7a released let-7 miRs via exosomes into the extracellular environment to maintain their oncogenic potential [59] .
Cancer cell-derived exosomes and their miR cargo can be functionally transferred to the cells of the TME, where they modulate gene expression and lead to amplified malignant potential of the tumor. Some of the pro-tumoral roles of cancer cell exo-miRs in the recipient cells include: inactivation or shift of immune cell responses, transfer of drug resistance, increased angiogenesis, increased invasiveness, priming of the pre-metastatic niche, and enhanced epithelial to mesenchymal (EMT) transition (Table 1 ). In the TME, dendritic cells (DCs) shift from effective antigen presenting cells to negative regulators of immune responses, and this shift seems mediated by exomiRs. Pancreatic cancer-derived exosomes downregulate the expression of TLR4 in DCs via transfer of miR-203 [60] . TLR4 has an important role in the recognition of the damage-associated molecular patterns (DAMPs). Pancreatic cancer exosomes have increased expression of miR-203, and DCs treated with those exosomes show significant downregulation of TLR4. In another study, the exosomes from docetaxel (doc)-resistant breast cancer cell lines were isolated and co-cultured with doc-sensitive breast cancer cells, leading to the upregulation of 20 miRs in the sensitive breast cancer cells. Target gene prediction and pathway analysis showed that the up-regulated miRs might be responsible for the lack of response to therapy. Those results sugest that drug-resistant cancer cells may spread chemoresistance to sensitive cells by releasing exosomes, and these effects could be partly attributed to the miR cargo of exosomes [61] . Yamada et al. found that the incubation of colorectal cancer cell-derived microvesicles with human endothelial cells (HUVECs) increased proliferation, migration, and tube formation of HUVECs. The colorectal cancer cells shuttled miR-1246 into HUVECs, which silenced promyelocytic leukemia protein (PML) and activated Smad 1/5/8 signaling (not Smad 2/3 which inactivates HUVEC proliferation) [62] . miR-10b was highly expressed in MDA-MB-231 cells compared to non-metastatic breast cancer cells or non-malignant breast cells. Additionally, miR-10b was highly secreted into medium via exosomes. nSMase2 promotes the loading of miR-10b into exosomes of breast cancer cells [63] . Upon co-culturing of those tumoral miR-10b loaded exosomes with non-metastatic mammary epithelial breast cells (HMLE cells), the HMLE cells acquired invasion ability [63] .
The pre-metastatic niche supports the soil and seed theory proposed by Paget, where tumors prepare selected organs for metastasis. Tumor cells utilize exo-miRs to educate the selected host tissues toward a pro-metastatic phenotype. Metastatic rat adenocarcinoma BSp73ASML (ASML)-derived exosomes carry levels of miR-494 and miR-542-3p significantly higher than the secreting cells. Those two miRs enhanced the transcription of matrix metalloproteinases and downregulated cadherin-17 (cdh-17) in a preferential site of metastasis: the lymph node [64] . The miR-200 family is specifically involved in the regulation of EMT. It was found that EVs of breast cancer cells were enriched with miR-200. Murine and human breast cancer cell EVs transferred miR-200 to nonmetastatic cells and promoted EMT [65] .
Most studies focused on exo-miRs secreted by cancer cells to modulate cells of the TME. However, there is some evidence that exo-miRs secreted by TME can alter gene expression of cancer cells and promote their [66] . TAMs are important cellular players in the TME, involved in tumor progression and metastasis. However, the mechanisms underlying the pro-tumoral interactions of TAMs and cancer cells are not fully understood. One possible explanation is that TAMreleased exosomes deliver oncogenic miRs to breast cancer cells. MiR-223 is upregulated in TAMs and is secreted in TAM-derived exosomes. Upon co-culture of breast cancer cells (MDA-MB-231 and SKBR3) with TAMs without direct cell-cell contact, miR-223 was significantly up-regulated in co-cultured breast cancer cells. The results of functional assay showed that miR-223 increased the invasive potential of breast cancer cells via activation of the Mef2c-β-catenin pathway [67] . Two studies showed an important role for exo-miRs from MSCs in promoting tumor growth. MSC exosomes isolated from bone marrow of patients with multiple myeloma promoted tumor growth and metastasis. Those MSC-derived exosomes showed significant downregulation of an important tumor suppressor, miR-15a [68] . EVs derived from serum-deprived human MSCs (SDMSCs) were enriched with miR-21 and -34a compared to MSCs. Furthermore, co-injection of EVs from SD-MSCs with breast cancer cells (MCF-7) into immunodeficient mice promoted breast cancer growth [69] .
The crosstalk between cancer cells and host cells within the TME appears to be effected by additional miR-mediated mechanisms, beyond the alteration of gene expression in recipient cells by binding to their target mRNA. Our lab has shown that some of the exomiRs secreted by cancer cells act as ligands of Toll-like Receptor 8 (TLR8) in TAMs, promoting tumor growth, dissemination, and resistance to therapy (Figure 1) [70, 71] . Thus, TLR8 can be considered the founding member of a class of molecules we call the miRceptors (defined as a receptor for miRs) [72] . In 2012, we showed that NonSmall Cell Lung Cancer (NSCLC)-derived exosomes were enriched for miR-21 and -29a. The NSCLC exosomes were taken up by surrounding TAMs at the tumor interface and transferred to TAM endosomes, where miR-21 and -29a were directly bound to TLR8 and triggered a TLR8-mediated activation of the NF-κB signaling. The NF-κB activation led to increased expression of pro-inflammatory cytokines IL-6 and TNF-α, further promoting the metastatic potential of NSCLC [70] . Recently, we have shown that this mechanism of "education" of TAMs also occurs in neuroblastoma (NBL) and several other types of cancers ( Figure 1 ) [71, 73] . NBL-secreted exosomes were enriched in miR-21 (but not in miR-29a), which was taken up by Figure 1 . Reciprocal exchange of exosomic miRs between cancer cells and cells of TME to promote tumorigenesis. Exo-miRs are transferred from cancer cells to cells of TME where they regulate gene expression by direct interactions with target mRNA and promote formation of stable TME (1) . Cancer cell exo-miRs can also bind the TLR8 receptor in TME cells leading to secretion of oncogenic exosomic miRs by TME cells causing increased cancer cell proliferation and drug resistance (2) . Cancer cells and/or the cells of TME secrete soluble factors that modulate endogenous miR expression and promote tumoral phenotype (3 and 4) . The tumoral role of extracellular miRs that are outside of vesicles is not currently fully understood (5 surrounding TAMs. miR-21 then bound to TLR8, leading to increased expression of the oncogenic miR-155 in a TLR8-and NF-κB-dependent manner. miR-155 was then shuttled back to NBL cells, where miR-155 targeted the inhibitor of telomerase TERF1, thus increasing telomerase activity and resistance of NBL cells to cisplatin (CDDP). These studies confirm a central role of exosomic miR exchange between cancer cells and the TME in orchestrating the biology of cancer growth and the development of mechanisms of resistance to treatments.
Exosomic miRs as non-invasive cancer biomarkers
Circulating exosomic miRs are emerging as important non-invasive biomarkers in cancer diagnosis, prognosis, and treatment response due to their ability to stably persist in body fluids of patients. Exosomes reflect their tissue of origin through the expression of tissue specific surface proteins. Additionally, there is a significant difference in the amount and composition of exo-miRs between cancer patients and healthy controls [33] . Lawrie and colleagues were the first to demonstrate the presence of extracellular miR-21 in the serum of cancer patients, and to show that serum levels of miR-21 were associated with relapse-free survival in patients with diffuse large B-cell lymphoma [74, 75] . Taylor et al. first showed that miR signatures of exosomes derived from sera parallel miR profiling of the originating ovarian tumor cells, implying that serum exosomic miR profiling can be done when the tissue biopsy is unavailable or difficult, and may accurately reflect cancer's profile [75, 76] . Many susequent studies have also identified circulatory miR profiles in patient plasma/sera of different tumors, suggesting a potential therapeutic use in the circumvention of the biopsies as a way of diagnosis and prognosis (Table 2 ) [19] .
Several groups investigating the extracellular serum/ plasma miR profiles of prostate cancer patients have reported that miR-141 and -375 as the most promising markers associated with high-risk prostate cancer. However, none of these studies reported how the miR was packaged [77] . Bryant et al. isolated exosomes from the plasma of 78 prostate cancer patients and 28 healthy controls. They found 12 miRs that were differentially expressed between prostate cancer patients and the controls, and 11 miRs that were distinct between patients with metastasis compared to those with nonmetastatic disease. MiR-141 and -375 were confirmed as significantly associated with metastatic prostate cancer and detectable in circulating exosomes [78] . Castrationresistant prostate cancer (CRPC) is a metastatic, rapidly progressing prostate cancer that became resistant to androgen therapy. Serum circulating exosomic miR-375 85 mg/ml for the lung adenocarcinoma group versus 0.77 mg/ml for the control group. The miR concentration was 158.6 ng/ml for lung adenocarcinoma group versus 68.1 ng/ml in the control group. Consistent with a pro-tumoral role for exo-miRs, there was an unpregulation of exosome secretion in the lung adenocarcinoma group compared to normal controls in the circulation. Furthermore, the expression levels of signatory miRs were similar between the circulating exosomes and tumor derived cells, suggesting that circulatory exo-miRs could be useful for lung adenocarcinoma screening [82] . Circulating exo-miRs are important prognostic biomarkers for hematological malignancies For example, the ability to track minimal residual disease (MRD) in acute myeloid leukemia (AML) patients would allow timely treatment adjustments to prevent relapse, which is the major cause of mortality among these patients. Hornick and colleagues, identified a set of miRs (miR-150, miR-155, and miR-1246) that are enriched in AML exosomes, and which are also present in circulatory exosomes of leukemic xenografts relative to non-engrafted and healthy human CD34+ controls [83] .
Circulating exo-miRs are attractive biomarkers. However, there are some pitfalls that need to be addressed before they are fully introduced into the clinic as a prognostic mechanism. The detection methods of miRs are similar for cancer cell cytosolic miRs, cancer cell-derived exo-miRs, fluidic miRs, and fluidic exo-miRs. Commonly adapted detection methods include Northern blotting, qRT-PCR, miR array, Nanostring or next-generation sequencing. However, there are several methods to isolate exosomes, which introduce variability as why different studies detect different circulatory exo-miRs from the same tumors [84] . The serum levels of exosomic miR-21 were significantly higher in patients with hepatocellular carcinoma (HCC) relative to chronic hepatitis B, in a study conducted by Wang et al. [85] . However, Sohn and group found no significant correlation of serum exosomic miR-21 with HCC relative to chronic hepatitis B [86] . Sohn et al. found elevated levels of exosomic miR-18a, -221, and -222 in serum of patients with HCC compared to chronic hepatitis B patients. Both groups utilized different exosome isolation reagents, and also used different internal controls.
Lastly, the functions of circulating exo-miRs are not fully understood. There are currently no studies that address whether circulating exo-miRs are remnants of overexpressed exo-miRs in the TME or act as a TMEindependent new class of exo-miRs with their own biological pro-tumoral functions [72] .
based studies show that exosomes in circulation have a miR content similar to that of the originating tumor cells, making them ideal biomarkers. Conversely, TME or tumor tissue based exo-miR studies show that the miR cargo in exosomes within the TME is distinct from that of the parental tumor cell. It is warranted that studies are required that investigate the relatedness of circulation and tumor tissue exo-miRs to further expand on the biology of exo-miRs and their implications as cancer biomarkers.
